<DOC>
	<DOCNO>NCT01215149</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability Ad26.ENVA.01 Ad35-ENV low-risk HIV-uninfected healthy adult administer heterologous homologous prime-boost regimen different time interval .</brief_summary>
	<brief_title>Safety Immunogenicity Study Ad26-ENVA Ad35-ENV HIV Vaccines Healthy HIV-uninfected Adults</brief_title>
	<detailed_description>The study randomize , double-blind placebo-controlled trial assess order vector prim boosting ( Ad26 versus Ad35 ) , time boost ( 3 versus 6 month ) homologous versus heterologous regimen 3-month time interval . Groups A-D enrol Boston , MA , USA , Groups E-H enrol East African Clinical Research Centres Groups I-L enrol South African Clinical Research Centres . Volunteers screen 56 day vaccination follow 12 month second vaccination . Approximately 212 volunteer randomize receive either vaccine placebo within group ( A-L ) ; Groups A-D , Groups E-H Groups I-L randomize separately . Up 7 % over-enrolment ( approximately 15 volunteer ) allow facilitate enrolment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female , assess medical history , physical exam , laboratory test ; At least 18 year age day screen reach his/her 51st birthday day first vaccination ; Willing comply requirement protocol available followup plan duration study ; In opinion Principal Investigator designee , base Assessment Informed Consent Understanding ( AOU ) result , understood information provide potential risk link vaccination participation trial ; write informed consent provide volunteer studyrelated procedure perform ; Willing undergo HIV testing , risk reduction counselling , receive HIV test result commit maintain low risk behaviour trial duration define protocol ; If female childbearing potential , willing use effective nonbarrier method contraception ( oral injectable hormonal contraceptive ; intrauterine device [ IUD ] ) screen least 4 month last study vaccination ; Assessed clinic staff `` low risk '' HIV infection basis sexual behaviour within 12 month prior enrolment ; All female volunteer must willing undergo pregnancy test time point indicate protocol must test negative prior study vaccination ; All sexually active male ( unless anatomically sterile ) must willing use effective method contraception ( consistent condom use ) day first vaccination least 4 month last vaccination ; Willing forgo donation blood tissue study , test HIV positive due trial vaccination ( vaccineinduced HIV seropositivity ) , antiHIV antibody titer become undetectable . Exclusion Criteria Confirmed HIV1 HIV2 infection ; Any clinically relevant abnormality history examination include history immunodeficiency autoimmune disease ; use systemic corticosteroid ( use topical inhaled steroid permit ) ; immunosuppressive , anticancer , antituberculosis medication consider significant investigator within previous 6 month ; Any clinically significant acute chronic medical condition consider progressive , opinion investigator , make volunteer unsuitable participation study ; Reported risky behaviour HIV infection within 12 month prior vaccination , define protocol If female , pregnant planning pregnancy within 4 month last vaccination ; lactating ; Asthma require highdose oral inhaled corticosteroid ; Fever &gt; 100.4° F/38.0° C within 72 hour prior vaccine administration ; Bleeding disorder diagnose physician ( e.g. , factor deficiency , coagulopathy platelet disorder require special precaution ) ( Note : A volunteer state easy bruise bleeding , formal diagnosis IM injection blood draw without adverse experience eligible ) ; History splenectomy ; Any abnormal laboratory parameter define protocol ; Receipt liveattenuated vaccine within previous 60 day plan receipt within 60 day vaccination Investigational Product ( within 14 day live attenuated influenza vaccine [ LAIV ] ) ; receipt vaccine ( e.g. , influenza , pneumococcal ) , allergy treatment antigen injection tuberculin skin test within previous 14 day plan receipt within 14 day vaccination Investigational Product ; Receipt blood transfusion bloodderived product within previous 3 month ; Participation another clinical trial Investigational Product currently , within previous 3 month expect participation study ; Receipt another investigational HIV vaccine candidate ( Note : receipt HIV vaccine control placebo exclude volunteer participation documentation available Medical Monitor give approval ) ; History severe local systemic reactogenicity vaccine ( e.g. , anaphylaxis , respiratory difficulty , angioedema ) ; Confirmed diagnosis active hepatitis B , hepatitis C active syphilis ; Seizure disorder : A participant seizure last 3 year exclude . ( Not exclude : participant history seizures neither required medication seizure 3 year . ) ; Psychiatric condition precludes compliance protocol . Specifically excluded person psychosis within past 3 year , ongoing risk suicide , history suicide attempt gesture within past 3 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>HIV</keyword>
</DOC>